Vitae earns $14M milestone payment from Boehringer Ingelheim

Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.

“This program addresses several features of the metabolic syndrome, a combination of disorders, including abdominal obesity, high blood pressure and insulin resistance or glucose intolerance, all of which contribute to an increased risk of coronary heart disease, stroke and Type 2 diabetes.”

"Inhibition of 11beta-HSD-1 represents an important new mechanism of action for treating diabetic patients," commented Dr. Richard Gregg, Vitae's Chief Scientific Officer. "This program addresses several features of the metabolic syndrome, a combination of disorders, including abdominal obesity, high blood pressure and insulin resistance or glucose intolerance, all of which contribute to an increased risk of coronary heart disease, stroke and Type 2 diabetes." Dr. Gregg continued, "Boehringer Ingelheim and Vitae have worked well together on this program. We are very pleased with the quality of the lead candidate and look forward to further building its profile as it advances in the clinic."

Vitae and Boehringer Ingelheim initiated their strategic 11beta-HSD-1 alliance in October of 2007. Under the terms of that agreement, the companies combined their respective research programs, working together to identify and advance novel 11beta-HSD-1 inhibitors. Vitae has now achieved three performance milestones totaling $26 million of a potential $300 million under the collaboration. Vitae is also eligible to receive royalty payments from Boehringer Ingelheim on sales of products commercialized under the collaboration.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Intensive blood pressure treatment reduces cardiovascular risk in people with Type 2 diabetes